AtriCure, Inc. (NASDAQ:ATRC) Stock Rated “Moderate Buy” by Sell-Side Brokerages

Shares of AtriCure, Inc. (NASDAQ:ATRC) have received an average recommendation of “Moderate Buy” from the twelve ratings firms that are presently covering the company, MarketBeat.com reports. Five investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $53.30.

A number of analysts recently weighed in on ATRC shares. Needham & Company LLC upped their price objective on shares of AtriCure from $45.00 to $64.00 and gave the stock a “buy” rating in a research note on Wednesday, September 2nd. Stifel Nicolaus set a $65.00 target price on shares of AtriCure in a research report on Thursday, September 17th. Weiss Ratings upgraded shares of AtriCure from a “sell (d+)” rating to a “hold (c-)” rating in a report on Wednesday, August 19th. Freedom Capital cut shares of AtriCure from a “strong-buy” rating to a “hold” rating in a research report on Friday. Finally, Raymond James Financial set a $52.00 price objective on shares of AtriCure in a research note on Tuesday, July 21st.

Insider Buying and Selling

In other news, Director Sven Wehrwein sold 25,000 shares of AtriCure stock in a transaction on Tuesday, July 28th. The stock was sold at an average price of $37.84, for a total value of $946,000.00. Following the transaction, the director directly owned 40,518 shares in the company, valued at approximately $1,533,201.12. This trade represents a 38.16% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Vinayak Doraiswamy sold 6,000 shares of AtriCure stock in a transaction on Tuesday, July 28th. The shares were sold at an average price of $38.88, for a total value of $233,280.00. Following the completion of the transaction, the insider owned 86,511 shares in the company, valued at $3,363,547.68. This represents a 6.49% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 74,868 shares of company stock valued at $3,317,897 over the last ninety days. Company insiders own 4.00% of the company’s stock.

Institutional Investors Weigh In On AtriCure

A number of hedge funds have recently made changes to their positions in ATRC. BlackRock Inc. bought a new stake in AtriCure during the second quarter valued at about $125,198,000. Bank of America Corp DE bought a new position in AtriCure in the second quarter worth about $24,465,000. Grandeur Peak Global Advisors LLC bought a new position in AtriCure in the second quarter worth about $16,435,000. Osterweis Capital Management Inc. purchased a new stake in shares of AtriCure during the second quarter valued at about $14,028,000. Finally, Connor Clark & Lunn Investment Management Ltd. purchased a new stake in shares of AtriCure during the second quarter valued at about $9,388,000. 99.11% of the stock is currently owned by hedge funds and other institutional investors.

AtriCure Trading Up 2.9%

Shares of NASDAQ ATRC opened at $55.14 on Friday. AtriCure has a twelve month low of $25.36 and a twelve month high of $61.70. The firm has a market cap of $2.80 billion, a PE ratio of 262.58 and a beta of 1.24. The business has a fifty day simple moving average of $49.44 and a two-hundred day simple moving average of $36.38. The company has a quick ratio of 3.19, a current ratio of 4.22 and a debt-to-equity ratio of 0.14.

AtriCure (NASDAQ:ATRC) last posted its quarterly earnings results on Thursday, July 23rd. The medical device company reported $0.18 earnings per share (EPS) for the quarter. The business had revenue of $153.60 million for the quarter, compared to the consensus estimate of $151.80 million. AtriCure had a return on equity of 2.34% and a net margin of 1.85%.During the same quarter in the prior year, the company earned ($0.13) EPS. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. Analysts expect that AtriCure will post 0.29 earnings per share for the current fiscal year.

About AtriCure

AtriCure, Inc is a medical device company focused on developing and commercializing technologies for the treatment of atrial fibrillation (AF) and related cardiac conditions. Its products are used primarily in cardiac surgery and electrophysiology procedures to create surgical lesions that interrupt abnormal electrical signals in the heart.

The company’s portfolio includes the AtriCure Isolator Synergy ablation system, cryoablation products sold under the cryoICE brand, and the AtriClip system for the exclusion of the left atrial appendage, a potential source of blood clots in patients with AF.